Table 1 Rate of discontinuation of three tumor necrosis factor antagonists; reasons for discontinuation and rank of treatment
TNF antagonist | Reason for discontinuation | Rate per 100 patient years exposed | |
|---|---|---|---|
First treatment | Second treatment | ||
Infliximab | Adverse events | 6.5 | 32.7 |
Lack of efficacy | 4.7 | 38.5 | |
Etanercept | Adverse events | 3.8 | 6.1 |
Lack of efficacy | 3.6 | 9.3 | |
Adalimumab | Adverse events | 7.2 | 12.5 |
Lack of efficacy | 3.2 | 12.5 | |